CTOs on the Move

Pure Bioscience

www.purebio.com

 
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE`s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate (SDC)- based antimicrobials, represent innovative advances in diverse markets and lead today`s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.purebio.com
  • 771 Jamacha Road Suite 512
    El Cajon, CA USA 92019
  • Phone: 619.596.8600

Executives

Name Title Contact Details
Jason Kawata
 Vice President of Technology, Food Division Profile

Similar Companies

Novartis Animal Health, US

Novartis Animal Health, US is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ParaTechs

ParaTechs is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InGeneron

Founded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research. Headquartered in Houston, Texas,

Conversant Biologics

Conversant Biologics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exscientia

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We`ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.